FactorPad
Build a Better Process

Stock Risk Measures for Reata Pharmaceuticals Inc-A

A quantitative factor review, as of September 30, 2020.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
by Paul Alan Davis, CFA
Updated: October 01, 2020
See how we arrive at an overall risk score of 64 for RETA below.

/ factorpad.com / stocks / f49dfm.html


An ad-free and cookie-free webpage by FactorPad


RETA Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Reata Pharmaceuticals Inc-A. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how RETA stock compares to 2,000+ US-based stocks, and to peers in the Health Technology sector and Pharmaceuticals: Major industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. S├╝dhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

Identity

Sector and Industry

Share Data

Shares and Float

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f49dfm.html


RETA stock risk
REATA PHARMACEUTICALS INC-A stock beta
RETA risk report
RETA f49dfm
RETA risk analysis
RETA volatility
REATA PHARMACEUTICALS INC-A credit risk
RETA liquidity risk
RETA leverage
RETA valuation
RETA systematic risk
RETA specific risk
REATA PHARMACEUTICALS INC-A volatility
RETA analysis
RETA financial ratio

This is a new resource, spread the word, tell a friend